

Fluoroquinolone Therapy in *Staphylococcus aureus* Infections: Where Do We Stand?

Neeta D Gade, Mohiuddin S Qazi

Department of Microbiology, Government Medical College, Nagpur, Maharashtra, India

Address for correspondence: Dr. Neeta D Gade, E-mail: neetagade21@gmail.com

ABSTRACT

Aim: The study aimed to evaluate the utility of various commonly used fluoroquinolones against *Staphylococcus aureus* isolates.

Materials and Methods: A total of 250 isolates of *S. aureus* were studied from different clinical specimens like blood, pus, wound swabs, sputum, ear swabs, and body fluids between November 2009 and December 2011. All the isolates were tested for their susceptibility to fluoroquinolones and other antimicrobial agents by Kirby-Bauer disc diffusion method using criteria of standard zone of inhibition. Methicillin-resistant *S. aureus* (MRSA) detection was done by cefoxitin disk diffusion method. The MRSA isolates were tested for minimum inhibitory concentration (MIC) to vancomycin by E-test strips. All the MRSA strains were sent to National Staphylococcal Phage-typing Centre, Maulana Azad Medical College, New Delhi for phage typing.

Results: A total of 107 strains of *S. aureus* (42.8%) were detected as MRSA. Multidrug resistance was observed among the MRSA strains more commonly than among the MSSA stains. Among the fluoroquinolones, maximum resistance in MRSA was seen to ciprofloxacin (92.5%), followed by ofloxacin (80.4%). None of the *S. aureus* isolates showed resistance to vancomycin and linezolid. The MICs of vancomycin for the MRSA tested ranged from 0.5 to 2 µg/ml. Phage typing pattern of 107 MRSA isolates revealed that 37 (34.6%) MRSA isolates were nontypeable and 70 (65.4%) were typeable.

Conclusion: Ciprofloxacin can no longer be used in empirical therapy against MRSA infections. Use of other members of fluoroquinolone should be limited only to those strains that show laboratory confirmation of their susceptibility. Vancomycin remains the drug of choice to treat MRSA infections.

Key words: Fluoroquinolones, methicillin-resistant *S. aureus*, phage typing, *Staphylococcus aureus*

INTRODUCTION

Staphylococcus aureus has been recognized as one of the most devastating persistent human pathogen that contributes toward hospital infection worldwide. It causes variety of infections, ranging from minor skin diseases to life-threatening endocarditis.^[1] With the emergence of methicillin resistance among *S. aureus* during the 1960s, the effectiveness of therapy of staphylococcal infections with penicillins and cephalosporins became questionable.^[2]

Methicillin-resistant *S. aureus* (MRSA) is difficult to treat and has very limited treatment options. Vancomycin is the only drug of choice.^[2] However, its high cost, difficulty in supervising intravenous (IV) administration, and several serious adverse drug reactions limit its routine use. In addition, there have been many reports of development of low grade to absolute resistance even to vancomycin from many parts of the globe.^[3,4]

The quinolones antibiotics have been proposed as a possible alternative to parenteral vancomycin therapy on the basis of several *in vitro*^[5] and *in vivo* animal model data.^[6] Not much data is available concerning quinolone resistance in *S. aureus* from this region. Therefore, the present study was undertaken to evaluate the utility of various commonly used fluoroquinolones against *S. aureus*.

Access this article online	
Quick Response Code: 	Website: www.jlponline.org
	DOI: 10.4103/0974-2727.119862

MATERIALS AND METHODS

The study was performed between November 2009 and December 2011 in the Department of Microbiology at our tertiary care hospital. A total of 250 isolates of *S. aureus* were isolated from 2850 different clinical specimens like blood, pus, wound swabs, sputum, ear swabs, and body fluids. Only one isolate per patient was included in the study. All the isolates were tested for their susceptibility to ciprofloxacin (5 µg), ofloxacin (5 µg), levofloxacin (5 µg), gatifloxacin (5 µg), moxifloxacin (5 µg), sparfloxacin (5 µg), penicillin (10 unit), tetracycline (30 µg), cotrimoxazole (25 µg), erythromycin (15 µg), gentamicin (10 µg), pristinamycin (15 µg), vancomycin (30 µg), and linezolid (30 µg) by Kirby-Bauer disc diffusion method using criteria of standard zone of inhibition. MRSA detection was done by ceftioxin disk diffusion method.

The MRSA isolates were tested for minimum inhibitory concentration (MIC) to vancomycin by E-test strips (Hi-media laboratories Pvt., Ltd., Mumbai).

All the MRSA strains were sent to National Staphylococcal Phage-typing Centre, Maulana Azad Medical College, New Delhi for phage typing.

RESULTS

Out of the 250 clinical isolates of *S. aureus*, maximum resistance was noted to penicillin (89.2%), followed by co-trimoxazole (72.0%) and ciprofloxacin (57.6%). None of the *S. aureus* isolates showed resistance to vancomycin and linezolid [Table 1]. Maximum susceptibility among the fluoroquinolones tested was to moxifloxacin (78.8%), followed by sparfloxacin (75.6%). Also, 94 (37.6%) isolates of *S. aureus* were sensitive to all the fluoroquinolones and 33 (13.2%) isolates were resistant to all the fluoroquinolones tested.

In the present study, 107 strains (42.8%) were detected as MRSA. Most of the MRSA strains were isolated from pus/wound swabs and the others from blood and sputum.

Majority of the MRSA (58.8%) were from surgical specialty, followed by orthopedics (40%), and 87.9% MRSA isolates were obtained from inpatient wards and 12.1% from OPDs.

Among the fluoroquinolones, maximum resistance in MRSA was seen to ciprofloxacin (92.5%), followed by ofloxacin (80.4%), gatifloxacin (53.3%), levofloxacin (49.5%),

sparfloxacin (45.8%), and moxifloxacin (39.3%). Of the 107 MRSA isolates, 26 (24.3%) MRSA isolates were found to be resistant to all the six fluoroquinolones tested. Only eight (7.5%) MRSA isolates were susceptible to all the six fluoroquinolones [Tables 2 and 3].

Table 1: Antimicrobial susceptibility pattern of *S. aureus* on disk diffusion (n=250)

	Sensitive number (%)	Resistant number (%)
Antibiotics		
Penicillin	27 (10.8)	223 (89.2)
Cotrimoxazole	70 (28.0)	180 (72.0)
Tetracycline	188 (75.2)	62 (24.8)
Gentamicin	184 (73.6)	66 (26.4)
Erythromycin	156 (62.4)	94 (37.9)
Pristinamycin	246 (98.4)	04 (1.6)
Vancomycin	250 (100)	0
Linezolid	250 (100)	0
Fluoroquinolones		
Ciprofloxacin	106 (42.4)	144 (57.6)
Ofloxacin	122 (48.8)	128 (51.2)
Gatifloxacin	168 (67.2)	82 (32.8)
Levofloxacin	174 (69.6)	76 (30.4)
Sparfloxacin	189 (75.6)	61 (24.4)
Moxifloxacin	197 (78.8)	53 (21.2)

Table 2: Comparison of antibiotic resistance pattern among MRSA and MSSA isolates

	MSSA (n=143) Resistant number (%)	MRSA (n=107) Resistant number (%)
Antibiotics		
Penicillin	116 (81.1)	107 (100)
Cotrimoxazole	84 (58.7)	96 (89.7)
Tetracycline	17 (11.9)	45 (42.1)
Gentamicin	05 (3.5)	61 (57)
Erythromycin	28 (19.9)	66 (61.7)
Pristinamycin	0	04 (3.7)
Vancomycin	0	0
Linezolid	0	0
Fluoroquinolones		
Ciprofloxacin	45 (31.5)	99 (92.5)
Ofloxacin	42 (29.4)	86 (80.4)
Gatifloxacin	25 (17.5)	57 (53.3)
Levofloxacin	23 (16.1)	53 (49.5)
Sparfloxacin	12 (8.4)	49 (45.8)
Moxifloxacin	11 (7.7)	42 (39.3)

MSSA: Methicillin-sensitive *S. aureus*, MRSA: Methicillin-resistant *S. aureus*

Table 3: Phenotypic resistance patterns of *S. aureus* for six fluoroquinolones

Resistance patterns	MRSA (n=107)	MSSA (n=143)	Total (n=250)
Resistant to all FQ (%)	26 (24.3)	07 (4.9)	33 (13.2)
Resistant only to CIP (%)	07 (6.5)	08 (5.6)	15 (6.0)
Resistant to CIP but sensitive to at least one of other FQ tested (%)	69 (64.5)	38 (26.6)	107 (42.8)
Sensitive to all FQ (%)	08 (7.5)	86 (60.1)	94 (37.6)

MSSA: Methicillin-sensitive *S. aureus*, MRSA: Methicillin-resistant *S. aureus*, CIP: Ciprofloxacin, FQ: Fluoroquinolones

The MICs of vancomycin for the MRSA tested ranged from 0.5 to 2 µg/ml [Figure 1].

Phage-typing pattern of 107 MRSA isolates revealed that 37 (34.6%) MRSA isolates were nontypeable and 70 (65.4%) were typeable. Among the typeable isolates, 26 (24.3%) belonged to group III, 17 (15.9%) to group I, 5 (4.7%) to group II, 15 (14.0%) to mixed group, 06 to group III and the miscellaneous group, and 1 to the miscellaneous group.

DISCUSSION

Over the last four decades, MRSA has spread throughout the world, and its prevalence is soaring worldwide, as evident from many studies; however, there are considerable differences between countries.^[7] In this study, 42.8% of the total isolates of the *S. aureus* were MRSA. Other studies have also shown such a high MRSA prevalence from various parts of the country ranging from 31-44%.^[8,9] The present study showed an alarmingly high percentage of MRSA infection in this hospital. Such a high prevalence of MRSA may be due to several factors. The indiscriminate use of antibiotics, sub-therapeutic dosage, improper monitoring in the administration of various antibiotics, patient's compliance, and unethical treatment before visiting the hospital might have been contributing factors.^[8]

Comparison of antibiotic resistance pattern among MRSA and methicillin-sensitive *S. aureus* (MSSA) isolates showed that resistance to fluoroquinolones as well as to other antibiotics tested was significantly higher in MRSA isolates than in MSSA isolates ($P < 0.0001$). Resistance of MRSA to penicillin (100%), cotrimoxazole (97%), and erythromycin (61.7%) was marked. High resistance to these drugs has also been reported in other studies.^[8,10,11]



Figure 1: Vancomycin MIC by E-test

The development and spread of multiple antibiotic-resistant MRSA have gained much attention over the years.^[2,10] Fluoroquinolone compounds such as ciprofloxacin and norfloxacin, first synthesized in the 1980s, were found to have extended antimicrobial spectra that included gram-positive bacteria, and were hoped to be useful in eradicating MRSA.^[6] However, since these compounds became available for clinical use, resistance among MRSA has been observed in different parts of the world.^[10,11]

In the present study, significantly higher percentage (92.5%) of MRSA isolates showed resistance to ciprofloxacin. Similar results of over 90% resistance have been reported in some studies from India^[12] and Pakistan.^[13] Mehta *et al.*,^[14] reported that resistance to ciprofloxacin had steadily increased from 39% in 1992 to 68% in 1996.

If such resistance is found in healthcare units, ciprofloxacin may not be useful as a first-line antibiotic. It has been reported that ciprofloxacin resistant isolates tend to show increased resistance to other antibiotics, including aminoglycosides.^[15,16]

In the present study, 80.4% MRSA showed resistance to ofloxacin, 53.3% to gatifloxacin, 49.5% to levofloxacin, and 45.8% to sparfloxacin. Lower resistance (39.3%) was noted to moxifloxacin. Different pattern of quinolone resistance was found among the ciprofloxacin resistant and susceptible isolates, and 24.3% MRSA isolates were found to be resistant to all six fluoroquinolones tested.

This different patterns and levels of resistance may arise following exposure to different quinolones, and different strains may produce different types of resistance.^[17]

In the present study, linezolid and vancomycin were found to be useful drugs in treating MRSA infections. None of the MRSA isolates showed resistance to vancomycin as well as to linezolid. The MICs values of vancomycin for all the MRSA ranged from 0.5 to 2 µg/ml in our study.

In the present study, 3.7% MRSA isolates were resistant to pristinamycin. Many studies reported different range of resistance to pristinamycin ranging from 0% to 44%.^[18]

Typing of MRSA strains is necessary for thorough epidemiological investigations of sources and modes of spread of these strains in hospitals and to design appropriate control measures.^[19] In the present study, of 107 MRSA isolates, 37 (34.6%) isolates were nontypeable, and 65.4% were typeable. Among the typeable isolates, most strains belonged to group III. In this study, the affinity of MRSA

strains to phages of group III was observed, although there were variations in their specific phage pattern. In view of high percentage of nontypeability among MRSA, there is a need for newer set of phages for MRSA typing.

CONCLUSION

In conclusion, *S. aureus* showed resistance to most of the antimicrobials in varying proportion, except to vancomycin and linezolid, to which the isolates were 100% sensitive. The percentage of MRSA among all *S. aureus* isolates was 42.8%. MRSA strains showed 100% resistance to penicillin. The study revealed that MRSA with associated multidrug resistance is common in this region. Most strains of MRSA were nontypeable using routine phages. There is a need to develop a local set of MRSA phages for improvement of typeability.

From the data, it appears that, over the period of last 15 years, MRSA have also acquired resistance to many commonly used fluoroquinolones. Ciprofloxacin can no longer be used as an empirical therapy against MRSA infections. Other members of quinolones may be used in *S. aureus* infections empirically in less serious selected cases. They may be continued after they show laboratory confirmation of their susceptibility.

Vancomycin is the mainstay of therapy in MDR MRSA infections and should be used judiciously. Looking at the possibility of emergence of resistance to the drug, newer agents like linezolid and pristinamycin may provide a valuable option for the treatment of MRSA infections.

ACKNOWLEDGMENT

The authors acknowledge the help provided by National Staphylococcal Phage-typing Centre, Maulana Azad Medical College, New Delhi for phage typing.

REFERENCES

1. Chambers HF. The changing epidemiology of *Staphylococcus aureus*. *Emerg Infect Dis* 2001;7:178-82.
2. Tiwari HK, Das AK, Sapkota D, Sivarajan K, Pahwa VK. Methicillin resistant *Staphylococcus aureus*: Prevalence and antibiogram in a tertiary care hospital in western Nepal. *J Infect Dev Ctries* 2009;3:681-4.

3. Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant *Staphylococcus aureus*: A 20 year study in a large French teaching hospital, 1983-2002. *J Antimicrob Chemother* 2006;57:506-10.
4. Bal M, Saha B, Singh AK, Ghosh A. Identification and characterization of a vancomycin-resistant *Staphylococcus aureus* isolated from Kolkata (South Asia). *J Med Microbiol* 2008;57:172-9.
5. Foster JK, Joseph R, Lentino RS, Divincenzo C. Comparison of *in vitro* activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant *Staphylococcus aureus* by time-kill kinetic studies. *Antimicrob Agents Chemother* 1986;30:823-7.
6. Gilbert MJ, Boscia A, Kobasa WD, Kaye D. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 1986;29:461-3.
7. Randrianirina F, Soares JL, Ratsima E, Carod JF, Combe P, Grosjean P, et al. *In vitro* activities of 18 antimicrobial agents against *Staphylococcus aureus* isolates from the Institute Pasteur of Madagascar. *Ann Clin Microbiol Antimicrob* 2007;6:5.
8. Anbumani N, Kalyani J, Mallika M. Prevalence of methicillin-resistant *Staphylococcus aureus* in a Tertiary Referral Hospital in Chennai, South India. *Indian J Pract Doct* 2006-08-2006-09;3.
9. Tyagi A, Kapil A, Singh P. Incidence of methicillin resistant *Staphylococcus aureus* (MRSA) in pus samples at a tertiary care hospital, AIIMS, New Delhi. *J Indian Acad Clin Med* 2008;9:33-5.
10. Tiwari HK, Sapkota D, Sen RM. High prevalence of multidrug-resistant MRSA in a tertiary care hospital of northern India. *Infect Drug Resist* 2008;1:57-61.
11. Pai V, Rao VI, Rao SP. Prevalence and antimicrobial susceptibility pattern of methicillin-resistant *Staphylococcus aureus* [MRSA] isolates at a tertiary care hospital in Mangalore, South India. *J Lab Physicians* 2010;2:82-4.
12. Sarma JB, Ahmed GU. Characterization of methicillin resistant *S. aureus* strains and risk factors for acquisition in a teaching hospital in northeast India. *Indian J Med Microbiol* 2010;28:127-9.
13. Qureshi AH, Rafi S, Qureshi SM, Ali AM. The current susceptibility patterns of methicillin resistant *Staphylococcus aureus* to conventional anti-staphylococcus antimicrobials at Rawalpindi. *Pak J Med Sci* 2004;20:361-4.
14. Mehta AP, Rodrigues C, Sheth K, Jani S, Hakimiyan A, Fazalbhoy N. Control of methicillin resistant *Staphylococcus aureus* in a tertiary care Centre: A five-year study. *J Med Microbiol* 1998;16:31-4.
15. Fernandez CJ, Ackerman VP. *In vitro* studies of ciprofloxacin and survey of resistance patterns in current isolates. *Diagn Microbiol Infect Dis* 1990;13:79-91.
16. Tsering DC, Pal R, Kar S. Methicillin-resistant *Staphylococcus aureus*: Prevalence and current susceptibility pattern in Sikkim. *J Glob Infect Dis* 2011;3:9-13.
17. Maple P, Hamilton JM, Brumfitt W. Ciprofloxacin resistance in methicillin- and gentamicin-resistant *Staphylococcus aureus*. *Eur J Clin Microbiol Infect Dis* 1989;8:622-4.
18. Deep A, Goel N, Sikka R, Chaudhary U, Yadav S, Gupta A, et al. Quinipristin dalfopristin resistance in gram positive bacteria: Experience from a tertiary care referral center in North India. *J Infect Dis Antimicrob Agents* 2008;25:117-21.
19. Mehndiratta PL, Bhalla P. Typing of Methicillin resistant *Staphylococcus aureus*: A technical review. *Indian J Med Microbiol* 2012;30:16-23.

How to cite this article: Gade ND, Qazi MS. Fluoroquinolone therapy in *Staphylococcus aureus* infections: Where do we stand?. *J Lab Physicians* 2013;5:109-12.

Source of Support: Nil. **Conflict of Interest:** None declared.